
NASDAQHealthcareMedical - Devices
أحدث البيانات المتاحة
13.065 US$
+0.375 US$ · +2.96%
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
الإغلاق السابق
13.065 US$
+0.375 US$ · +2.96%
بعد ساعات التداول
13.12 US$
+0.055 US$ · +0.42%
9 أكتوبر، 7:30 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
نطاق اليوم
السعر الحالي 13.065 US$
نطاق 52 أسبوعًا
السعر الحالي 13.065 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
85
قيمة جذابة جدًا
المشاعر
70
صعودي
المخاطر
42
مخاطر أعلى من المعتاد
الزخم
69
زخم متزايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
نطاق اليوم
السعر الحالي 13.065 US$
نطاق 52 أسبوعًا
السعر الحالي 13.065 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 568.09 مليون USD | 573.28 مليون USD | 512.35 مليون USD | 512.12 مليون USD | 430.9 مليون USD |
| تكلفة البضاعة المباعة | 185.66 مليون USD | 185.05 مليون USD | 184.15 مليون USD | 181.04 مليون USD | 128.19 مليون USD |
| الربح الإجمالي | 382.43 مليون USD | 388.23 مليون USD | 328.19 مليون USD | 331.08 مليون USD | 302.71 مليون USD |
| البحث والتطوير | 12.11 مليون USD | 13.64 مليون USD | 13.45 مليون USD | 23.85 مليون USD | 19.04 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 311.77 مليون USD | 327.09 مليون USD | 303.88 مليون USD | 332.13 مليون USD | 254.25 مليون USD |
| نفقات التشغيل | 323.88 مليون USD | 400.21 مليون USD | 409.92 مليون USD | 498.31 مليون USD | 290.65 مليون USD |
| مصاريف الفوائد | 26.49 مليون USD | 38.79 مليون USD | 40.68 مليون USD | 12.02 مليون USD | 1.11 مليون USD |
| الاستهلاك والإطفاء | 47.01 مليون USD | 49.56 مليون USD | 57.37 مليون USD | 55.4 مليون USD | 34.88 مليون USD |
| الدخل التشغيلي | 58.55 مليون USD | −11.98 مليون USD | −81.73 مليون USD | −167.23 مليون USD | 12.06 مليون USD |
| صافي الدخل | 22.73 مليون USD | −33.54 مليون USD | −156.23 مليون USD | −158.7 مليون USD | 19.38 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Avantis U.S. Small Cap Value ETFAVUV22.74 مليون0.07%30.85 مليار USD0.25%119.64 US$-0.41%
iShares Russell 2000 ETFIWM16.11 مليون0.02%78.27 مليار USD0.19%278.94 US$+0.49%
Vanguard Morningstar Total Stock Market ETFVTI15.88 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Extended Market ETFVXF7.43 مليون0.01%95.4 مليار USD0.05%235 US$+0.80%
Dimensional - US Small Cap ETFDFAS5.66 مليون0.02%33.87 مليار USD0.31%78.35 US$+0.32%
iShares Russell 2000 Growth ETFIWO5.59 مليون0.04%13.97 مليار USD0.24%356.78 US$+0.94%
Fidelity Enhanced Small Cap ETFFESM4.06 مليون0.06%6.41 مليار USD0.28%45.46 US$+0.46%
Vanguard Russell 2000 ETFVTWO3.78 مليون0.02%18 مليار USD0.06%112.66 US$+0.50%
Avantis U.S. Small Cap Value ETFAVUV
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
iShares Russell 2000 Growth ETFIWO
Fidelity Enhanced Small Cap ETFFESM
Vanguard Russell 2000 ETFVTWOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.